What caused the pre-market drop in the 22UA.F stock?

The pre-market decline was driven by heavy selling and risk-off flows for biotech names. Volume spiked to 1,130,267.00 shares, and investors reacted to valuation concerns, trial and regulatory headline risk, and broader sector rotation.

How safe is BioNTech’s balance sheet after the sell-off?

BioNTech shows strong liquidity: **cash per share €60.74** and a **current ratio 7.12**. Market cap is **€17,168,519,497.00**, supporting runway for R&D, though cash burn requires monitoring with upcoming results.

What price targets does Meyka AI forecast for 22UA.F stock?

Meyka AI's model projects a **monthly €57.40**, a **yearly €79.58**, and a **3-year €54.27**. The yearly target implies **~10.45%** upside from **€72.05**. Forecasts are model-based projections and not guarantees.

When is the next catalyst for BioNTech investors to watch?

The next major company-level catalyst is the earnings announcement scheduled for **2026-05-11**. Clinical trial readouts and partnership updates are other near-term events that could move the share price.

DE Stocks

Pre-market: BioNTech (22UA.F XETRA) down 17.09% to €72.05: outlook under pressure

ByHuzaifa Zahoor March 11, 2026March 11, 2026

The 22UA.F stock plunged -17.09% in pre-market trade to €72.05, marking one of the largest single-session drops since the stock’s 2025 volatility. Volume surged to 1,130,267.00 shares versus an average of 2,243.00, signaling heavy selling on XETRA in Germany. This drop follows weak sentiment around biotech valuations and headline risk tied to pipeline progress; we examine why the move happened, the balance-sheet buffer, and what traders should watch into the next sessions.